Key Points
- Director Luke Evnin sold 168,262 shares on April 30 at an average price of $0.72 for $121,148.64, a transaction executed under a pre-arranged Rule 10b5-1 trading plan and disclosed in an SEC filing.
- Between April 27 and May 4 Evnin sold a total of 480,530 shares across multiple tranches for roughly $352,835, reducing his stake by 8.61% to 1,785,687 shares valued at about $1.29 million.
- Shares opened at $0.69 (down ~4.6%), the company has a market cap of $33.5M, and analysts’ consensus is a Hold with a $3.75 target price.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $0.72, for a total transaction of $121,148.64. Following the transaction, the director directly owned 1,785,687 shares in the company, valued at approximately $1,285,694.64. This trade represents a 8.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total transaction of $34,533.36.
- On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $42,627.62.
- On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $39,025.71.
- On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total transaction of $69,650.76.
- On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.85, for a total transaction of $45,849.00.
Werewolf Therapeutics Stock Down 4.6%
HOWL opened at $0.69 on Tuesday. The firm has a market capitalization of $33.53 million, a P/E ratio of -0.51 and a beta of 0.41. The firm's 50 day moving average is $0.81 and its 200-day moving average is $0.88. Werewolf Therapeutics, Inc. has a 52-week low of $0.53 and a 52-week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.14. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.
Institutional Trading of Werewolf Therapeutics
Several institutional investors have recently added to or reduced their stakes in HOWL. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the first quarter valued at $79,000. Marshall Wace LLP bought a new stake in Werewolf Therapeutics during the second quarter valued at $113,000. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the second quarter valued at $48,000. Jane Street Group LLC bought a new stake in Werewolf Therapeutics during the second quarter valued at $409,000. Finally, Bank of America Corp DE increased its stake in Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Institutional investors own 64.84% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on HOWL shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Werewolf Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, April 7th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $3.75.
Read Our Latest Stock Report on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
